Shock-wave therapy in men with pelvic pain

Assessment the effect of focused extracorporeal shockwave therapy in pain management, erectile dysfunction and urinary symptoms in patients suffering from chronic pelvic pain syndrome – a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017082635911N1

Enrollment

Registered

2017-11-17

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pelvic Pain Syndrome (Chronic Prostatitis). Chronic prostatitis

Interventions

Intervention 1: Intervention : Cap tamsolusin (Abidi Co) 0.4 mg qhs 3 months Tab Alfen XL (Abidi Co) 100 mg Daily for 3 months Tab Baclofen (Abidi Co) 10 mg BD for 3 months Tab ofloxacin (Abidi Co) 30

Treatment - Drugs

Placebo

Intervention : Cap tamsolusin (Abidi Co) 0.4 mg qhs 3 months Tab Alfen XL (Abidi Co) 100 mg Daily for 3 months Tab Baclofen (Abidi Co) 10 mg BD for 3 months Tab ofloxacin (Abidi Co) 300 BD for 2 we

Control : Cap Tamsolusin (Abidi Co) 0.4 mg qhs for 3 months Tab Alfen XL (Abidi Co) 100 mg Daily for 3 month Tab Baclofen (Abidi Co) 10 mg BD for 3 months Tab Ofloxacin (Abidi Co) 300 mg BD for 2 w

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: >18 years old; definite diagnosis of CPPS; Symptomatic for at least 3 months; no treatment before; sign the informed consent Exclusion criteria: acute or chronic bacterial prostatitis; UTI in 1 recent year; history of prostate cancer or PSA>4; coagulation problems; history of hematuria, urethral stricture, urologic cancers, urolithiasis, neurogenic bladder, STDs, colorectal problems, inguinal hernia and varicocele; drug addiction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: before, 1 and 3 months after procedure. Method of measurement: Visual Analog Scale Questionnaire.;Qmax. Timepoint: before, 1 and 3 months after procedure. Method of measurement: Uroflowmetry.;Erectile Dysfunction. Timepoint: before, 1 and 3 months after procedure. Method of measurement: International Index of Erectile Function 5 Questionnaire.;Symptoms Severity. Timepoint: before, 1 and 3 months after procedure. Method of measurement: National Institute of Health Chronic Prostatitis Index Questionnaire.;Lower urinary Tract Symptoms. Timepoint: before, 1 and 3 months after procedure. Method of measurement: International Prostate Symptom Score Questionnaire.	—

Measure

Time frame

Pain. Timepoint: before, 1 and 3 months after procedure. Method of measurement: Visual Analog Scale Questionnaire.;Qmax. Timepoint: before, 1 and 3 months after procedure. Method of measurement: Uroflowmetry.;Erectile Dysfunction. Timepoint: before, 1 and 3 months after procedure. Method of measurement: International Index of Erectile Function 5 Questionnaire.;Symptoms Severity. Timepoint: before, 1 and 3 months after procedure. Method of measurement: National Institute of Health Chronic Prostatitis Index Questionnaire.;Lower urinary Tract Symptoms. Timepoint: before, 1 and 3 months after procedure. Method of measurement: International Prostate Symptom Score Questionnaire.

—

Secondary

Measure	Time frame
Hematuria. Timepoint: 1 and 3 months after procedure. Method of measurement: Inreview.;Hematospermia. Timepoint: 1 and 3 months after procedure. Method of measurement: Interview.;Post void residue. Timepoint: before, 1 and 3 months after. Method of measurement: uroflowmetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad Allameh

Shahid Beheshti University of Medical Sciences

farzadallame@gmail.com+98 21 2273 6386

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026